StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
37
This year
5
Publishing Date
2024 - 03 - 21
1
2024 - 03 - 08
1
2024 - 01 - 08
1
2024 - 01 - 04
1
2024 - 01 - 03
1
2023 - 10 - 25
1
2023 - 09 - 25
1
2023 - 09 - 12
1
2023 - 08 - 25
1
2023 - 06 - 26
1
2023 - 05 - 22
1
2023 - 02 - 23
1
2023 - 01 - 19
1
2023 - 01 - 04
1
2022 - 11 - 30
1
2022 - 09 - 16
1
2022 - 08 - 25
1
2022 - 07 - 25
1
2022 - 07 - 11
1
2022 - 07 - 05
1
2022 - 06 - 12
1
2022 - 05 - 11
1
2022 - 04 - 04
1
2022 - 03 - 28
1
2021 - 11 - 12
1
2021 - 11 - 11
1
2021 - 11 - 10
1
2021 - 11 - 04
1
2021 - 09 - 28
1
2021 - 09 - 16
1
2021 - 08 - 05
1
2021 - 07 - 29
1
2021 - 07 - 21
1
2021 - 06 - 22
1
2021 - 06 - 16
1
2021 - 05 - 28
1
2021 - 03 - 22
1
Sector
Consumer durables
1
Consumer non-durables
1
Health technology
37
Tags
Acquired
1
Alcohol use disorder
2
Application
2
Approval
4
Authorization
1
Awiqli
1
Bleeding
3
Children
1
Clearance
1
Diabetes
8
Disease
3
Disorders
1
Drug
1
Ema
1
Europe
2
Expected
2
Fda
2
Fda clearance
1
Fibrosis
1
First
1
Genetown
4
Glargine
1
Global
7
Growing
1
Growth
4
Haemophilia
1
Health
1
Heart
2
Hormone
1
Hypoglycemia
1
Insulin
2
Liver
3
Liver disease
2
Living
1
Market
9
Million
1
Money
2
N/a
28
Nash
1
New drug
1
Obesity
5
Ozempic
1
Patent
1
Pharma
1
Phase 1
3
Phase 2
2
Phase 3
1
Positive
1
Potential
2
Rare
1
Reach
2
Report
4
Research
5
Results
2
Risk
1
Roche
1
Sanofi
1
Sogroya
1
Treatment
34
Trial
7
Entities
3m company
21
Abbott laboratories
60
Abbvie inc.
121
Accuray incorporated
21
Adamis pharmaceuticals corporation
19
Adial pharmaceuticals, inc
22
Alnylam pharmaceuticals, inc.
38
Amgen inc.
47
Arcutis biotherapeutics, inc.
25
Arrowhead pharmaceuticals, inc.
21
Astellas pharma inc
51
Astrazeneca plc
52
Bausch health companies inc.
36
Biogen inc.
42
Biohaven pharmaceutical holding company ltd.
19
Bioxcel therapeutics, inc.
20
Boston scientific corporation
21
Brainsway ltd.
41
Bridgebio pharma, inc.
20
Bristol-myers squibb company
94
Cns pharmaceuticals, inc.
26
Coherus biosciences, inc.
28
Compass pathways plc
20
Ecolab inc.
47
Eli lilly and company
180
Fortress biotech, inc.
27
Gilead sciences, inc.
50
Glaxosmithkline plc
103
Hoth therapeutics, inc.
24
Incyte corporation
77
Intellia therapeutics, inc.
32
Jazz pharmaceuticals plc
20
Johnson & johnson
208
Karyopharm therapeutics inc.
33
Koninklijke philips n.v.
21
Medicinova, inc.
24
Medtronic plc
46
Merck & company, inc.
65
Moleculin biotech, inc.
27
Novartis ag
144
Novo nordisk a/s
37
Nrx pharmaceuticals inc
20
Orange
87
Perrigo company
21
Pfizer, inc.
74
Reata pharmaceuticals, inc.
28
Regeneron pharmaceuticals, inc.
57
Regenxbio inc.
25
Sanofi
293
Sorrento therapeutics, inc.
37
Takeda pharmaceutical company limited
53
Teleflex incorporated
21
Teva pharmaceutical industries ltd
79
Tg therapeutics, inc.
24
Tonix pharmaceuticals holding corp.
32
Ultragenyx pharmaceutical inc.
25
Verrica pharmaceuticals inc.
23
Vertex pharmaceuticals incorporated
27
Viatris inc.
46
Xylem inc.
35
Symbols
ABBV
3
ABCM
1
ABCZF
1
ALNY
6
AMGN
2
AMYT
1
APEN
1
AZN
2
AZNCF
2
BAX
1
BC
1
DTIL
1
GLAXF
3
GSK
4
JNJ
5
K
1
LLY
9
MDT
2
NVO
37
NVS
4
NVSEF
4
OMGA
1
PFE
2
SNY
7
SNYNF
7
TAK
2
TECH
1
TEVJF
1
ZEAL
1
Exchanges
Nasdaq
20
Nyse
37
Crawled Date
2024 - 03 - 21
1
2024 - 03 - 08
1
2024 - 01 - 08
1
2024 - 01 - 04
1
2024 - 01 - 03
1
2023 - 10 - 25
1
2023 - 09 - 25
1
2023 - 09 - 13
1
2023 - 08 - 25
1
2023 - 06 - 26
1
2023 - 05 - 22
1
2023 - 02 - 23
1
2023 - 01 - 19
1
2023 - 01 - 04
1
2022 - 11 - 30
1
2022 - 09 - 16
1
2022 - 08 - 25
1
2022 - 07 - 25
1
2022 - 07 - 11
1
2022 - 07 - 06
1
2022 - 06 - 12
1
2022 - 05 - 11
1
2022 - 04 - 04
1
2022 - 03 - 28
1
2021 - 11 - 12
1
2021 - 11 - 11
1
2021 - 11 - 10
1
2021 - 11 - 04
1
2021 - 09 - 28
1
2021 - 09 - 16
1
2021 - 08 - 05
1
2021 - 07 - 29
1
2021 - 07 - 21
1
2021 - 06 - 22
1
2021 - 06 - 16
1
2021 - 05 - 28
1
2021 - 03 - 22
1
Crawled Time
00:00
2
02:00
1
07:00
1
11:00
2
11:33
1
12:00
2
12:15
3
13:00
2
14:00
4
15:00
2
16:00
2
17:00
3
20:00
1
20:20
1
21:00
4
22:00
4
23:00
2
Source
www.biospace.com
9
www.globenewswire.com
13
www.prnewswire.com
15
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
treatment
entities :
Novo nordisk a::S
save search
Awiqli® (once-weekly basal insulin icodec) recommended for approval for the treatment of diabetes by the European regulatory authorities
Published:
2024-03-21
(Crawled : 16:00)
- globenewswire.com
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
-4.47%
|
O:
-1.04%
H:
1.6%
C:
0.64%
awiqli
approval
treatment
diabetes
insulin
FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight
Published:
2024-03-08
(Crawled : 20:00)
- prnewswire.com
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
Email alert
Add to watchlist
fda
obesity
first
treatment
risk
heart
COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment (insulin glargine U100 and insulin aspart) in people with type 2 diabetes
Published:
2024-01-08
(Crawled : 13:00)
- globenewswire.com
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
17.5%
|
O:
0.19%
H:
0.34%
C:
0.21%
treatment
glargine
trial
diabetes
insulin
Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases
Published:
2024-01-04
(Crawled : 11:00)
- globenewswire.com
OMGA
|
$2.565
6.43%
6.04%
390K
|
|
-6.23%
|
O:
92.31%
H:
20.0%
C:
1.24%
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
20.18%
|
O:
1.44%
H:
3.68%
C:
2.4%
treatment
research
therapeutics
Nalu Medical, Inc. Announces $65 Million Equity Financing to Advance Treatment for Chronic Neuropathic Pain
Published:
2024-01-03
(Crawled : 17:00)
- biospace.com/
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
21.96%
|
O:
-0.06%
H:
1.75%
C:
1.54%
million
treatment
Global Bleeding Disorders Treatment Market Surpasses $14 Billion in 2022, Expected to Reach $20.3 Billion by 2028
Published:
2023-10-25
(Crawled : 22:00)
- prnewswire.com
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-9.31%
|
O:
-4.69%
H:
0.69%
C:
-3.18%
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
27.81%
|
O:
-1.47%
H:
0.22%
C:
-0.83%
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-4.49%
|
O:
0.1%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-13.15%
|
O:
0.09%
H:
0.0%
C:
0.0%
bleeding
expected
reach
disorders
treatment
global
market
Valo Health and Novo Nordisk to collaborate to discover and develop novel treatments for cardiometabolic diseases using human data and artificial intelligence
Published:
2023-09-25
(Crawled : 12:00)
- globenewswire.com
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
36.4%
|
O:
-0.44%
H:
0.33%
C:
0.25%
health
Global Oral Proteins and Peptides Market Valued at $1.57 Billion in 2022, Driven by Rising Demand for Oral Treatments
Published:
2023-09-12
(Crawled : 00:00)
- prnewswire.com
AZNCF
|
$135.305
-4.19%
1.1K
|
Health Technology
|
2.33%
|
O:
0.89%
H:
0.37%
C:
-2.49%
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
26.59%
|
O:
-2.21%
H:
1.23%
C:
0.11%
AZN
|
$68.53
0.39%
0.39%
3.7M
|
Health Technology
|
1.37%
|
O:
-0.22%
H:
0.33%
C:
-1.1%
global
market
Global Obesity Treatment Market Poised to Reach $26.44 Billion by 2028, Fueled by Rising Prevalence and Innovative Interventions
Published:
2023-08-25
(Crawled : 02:00)
- prnewswire.com
PFE
A
|
$25.42
-1.05%
-0.04%
44M
|
Health Technology
|
-29.7%
|
O:
-0.06%
H:
1.52%
C:
0.66%
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
34.37%
|
O:
-0.34%
H:
1.29%
C:
0.93%
MDT
|
News
|
$79.08
-0.22%
0.0%
5.5M
|
Health Technology
|
-3.95%
|
O:
-0.98%
H:
1.19%
C:
0.82%
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-11.73%
|
O:
0.51%
H:
0.0%
C:
0.0%
ABBV
|
$164.25
1.05%
-0.76%
4M
|
Health Technology
|
11.38%
|
O:
-0.11%
H:
0.44%
C:
-0.22%
obesity
reach
treatment
global
market
Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency
Published:
2023-06-26
(Crawled : 07:00)
- globenewswire.com
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
-21.71%
|
O:
0.25%
H:
0.29%
C:
-1.41%
pharma
authorization
treatment
hypoglycemia
application
diabetes
Novo Nordisk A/S: Oral semaglutide 50 mg achieved 15.1% weight loss (17.4% if all people adhered to treatment) in adults with obesity or overweight in the OASIS 1 trial
Published:
2023-05-22
(Crawled : 15:00)
- globenewswire.com
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
-26.98%
|
O:
-0.04%
H:
0.86%
C:
0.02%
obesity
trial
Worldwide Recombinant Protein Industry to 2027: Elevating Prevalence of Several Chronic Diseases Along With the Increasing Demand for Novel Treatment Options Drives Growth
Published:
2023-02-23
(Crawled : 23:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-4.53%
|
O:
-2.11%
H:
0.0%
C:
0.0%
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
-12.85%
|
O:
-1.0%
H:
0.22%
C:
0.1%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-2.97%
|
O:
0.72%
H:
0.0%
C:
0.0%
TECH
|
$62.7
-2.05%
-2.09%
900K
|
Health Technology
|
-15.54%
|
O:
-1.43%
H:
0.25%
C:
-1.0%
AMGN
|
$264.07
-0.59%
-0.59%
2.2M
|
Health Technology
|
12.34%
|
O:
-0.33%
H:
0.1%
C:
-1.34%
ABCM
|
$23.99
0.0%
7.4M
|
Health Technology
|
68.0%
|
O:
-0.14%
H:
0.98%
C:
0.0%
treatment
growth
Global Bleeding Disorders Treatment Market Report 2022: Industry Trends, Share, Size, Growth, Opportunities and Forecasts 2021-2027
Published:
2023-01-19
(Crawled : 21:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-6.99%
|
O:
-2.08%
H:
0.0%
C:
0.0%
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-18.83%
|
O:
-0.19%
H:
0.8%
C:
0.62%
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
-11.47%
|
O:
-0.23%
H:
0.56%
C:
0.55%
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-14.61%
|
O:
0.34%
H:
0.01%
C:
-0.8%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-6.47%
|
O:
-0.41%
H:
0.0%
C:
0.0%
treatment
bleeding
global
report
market
Global Type 2 Diabetes Treatment Market Outlook Report 2022-2023 & 2027: Patent Cliff, Oral Antidiabetics, and Growing Focus on Accessibility and Affordability of Medicine Bolsters Growth
Published:
2023-01-04
(Crawled : 23:00)
- prnewswire.com
AZNCF
|
$135.305
-4.19%
1.1K
|
Health Technology
|
-1.98%
|
O:
-0.93%
H:
3.08%
C:
3.08%
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
-8.95%
|
O:
-0.89%
H:
1.18%
C:
0.52%
NVS
|
News
|
$93.08
-0.13%
0.86%
1.2M
|
Health Technology
|
1.35%
|
O:
-0.85%
H:
0.2%
C:
-0.29%
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-19.63%
|
O:
-0.62%
H:
0.54%
C:
-0.12%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-6.38%
|
O:
-3.07%
H:
0.0%
C:
0.0%
AZN
|
$68.53
0.39%
0.39%
3.7M
|
Health Technology
|
-1.78%
|
O:
-0.49%
H:
1.65%
C:
0.94%
treatment
patent
global
report
growing
diabetes
growth
market
iECURE Raises $65 Million to Advance In Vivo Gene Editing Programs for the Treatment of Rare Pediatric Liver Diseases
Published:
2022-11-30
(Crawled : 14:00)
- biospace.com/
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
2.62%
|
O:
2.1%
H:
0.56%
C:
0.56%
DTIL
|
$11.5
-10.65%
-11.91%
220K
|
Health Technology
|
890.0%
|
O:
1.54%
H:
4.55%
C:
3.79%
treatment
rare
liver
Global Bleeding Disorders Treatment Market Report 2022: Healthy Growth Expected Driven By Key Players Bayer, Pfizer, Octapharma & Others
Published:
2022-09-16
(Crawled : 16:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
16.59%
|
O:
0.74%
H:
0.91%
C:
-0.74%
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
20.66%
|
O:
-1.76%
H:
0.55%
C:
0.03%
NVS
|
News
|
$93.08
-0.13%
0.86%
1.2M
|
Health Technology
|
15.28%
|
O:
0.1%
H:
0.25%
C:
-0.21%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
142.6%
|
O:
-0.48%
H:
1.3%
C:
0.3%
BAX
|
News
|
$39.52
-0.13%
0.0%
2.8M
|
Health Technology
|
-32.68%
|
O:
-0.41%
H:
0.16%
C:
-0.94%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
13.38%
|
O:
-0.52%
H:
0.0%
C:
0.0%
AMGN
|
$264.07
-0.59%
-0.59%
2.2M
|
Health Technology
|
17.25%
|
O:
-0.34%
H:
2.35%
C:
1.87%
treatment
bleeding
global
report
expected
growth
market
Menopausal Hot Flashes Treatment Market Estimated to Rise at CAGR of 6% from 2019 to 2027, TMR Study
Published:
2022-08-25
(Crawled : 14:00)
- prnewswire.com
GLAXF
|
$20.2
-14.18%
510
|
Health Technology
|
23.66%
|
O:
0.03%
H:
0.0%
C:
-1.29%
PFE
A
|
$25.42
-1.05%
-0.04%
44M
|
Health Technology
|
-46.41%
|
O:
0.19%
H:
0.9%
C:
0.8%
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
13.19%
|
O:
-0.18%
H:
1.45%
C:
1.44%
NVS
|
News
|
$93.08
-0.13%
0.86%
1.2M
|
Health Technology
|
11.33%
|
O:
-0.28%
H:
0.13%
C:
0.04%
GSK
|
$39.6
-0.88%
0.0%
2.8M
|
Health Technology
|
18.1%
|
O:
0.0%
H:
0.63%
C:
0.6%
treatment
study
market
Global Acquired von Willebrand Disease (AvWD) Treatment Market Report 2022-2030 Featuring Key Players - Novo Nordisk A/S, Genentech, Inc., F. Hoffman-La Roche AG, Sanofi SA
Published:
2022-07-25
(Crawled : 14:00)
- prnewswire.com
GLAXF
|
$20.2
-14.18%
510
|
Health Technology
|
-6.05%
|
O:
0.0%
H:
0.0%
C:
0.0%
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
8.66%
|
O:
0.83%
H:
0.67%
C:
0.32%
GSK
|
$39.6
-0.88%
0.0%
2.8M
|
Health Technology
|
-6.36%
|
O:
0.76%
H:
0.19%
C:
-1.06%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-6.74%
|
O:
2.0%
H:
0.0%
C:
0.0%
treatment
global
disease
report
roche
acquired
sanofi
market
Novo Nordisk A/S: Mim8 phase 1 & 2 data demonstrates potential as once monthly treatment for people with haemophilia A
Published:
2022-07-11
(Crawled : 14:00)
- globenewswire.com
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
15.54%
|
O:
1.18%
H:
1.24%
C:
0.45%
treatment
haemophilia
potential
phase 1
Hemophilia Treatment Market to Reach $26.9 Bn, Globally, by 2031 at 7.5% CAGR: Allied Market Research
Published:
2022-07-05
(Crawled : 00:00)
- prnewswire.com
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
14.29%
|
O:
0.28%
H:
1.67%
C:
1.13%
treatment
research
market
← Previous
1
2
Next →
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
News
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
News
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.